Deal snapshot: Regeneron Acquires Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo.

MANews-(C)2009-2022

US-based biotechnology company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plans to purchase French healthcare group Sanofi's (NASDAQ: SNY) stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine, the company said.

The transaction is subject to merger...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT